asa statement glp-1 medications safe to continue before surgery in patients with diabetes and obesity The 2023 ASA position on
Description
This has raised concerns about their impact on cancer risk, spurring extensive research
A dietitian reviews the evidence, benefits, side effects, and key considerations.
In the past seven years, the proportion of new, commercial patients who are rejected for a launch brand increased from 37% to 56%, such that more than half of the attempts to initiate a new treatment in 2022 were unfilled the first year
One prescription, multiple diseases, and a cascade of transformative outcomes for the industry
"If you look at AI, there are tons of ETFs out there," Tema CEO Maurits Pot says
